FDA Approves Yorvipath for the Treatment of Hypoparathyroidism in Adults
Ascendis Pharma A/S announced the U.S. Food & Drug Administration (FDA) approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults.
- Yorvipath is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period.
- Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of parathyroid hormone that impact multiple organs and affects an estimated 70,000 to 90,000 people in the United States.
Source: Ascendis Pharma
